In-vitro Toxicology Testing Market Forecasts to 2030 - Global Analysis By Product Type (Software, Assay Kits, Equipment, Consumables and Other Product Types), Method, Technology, Toxicity Endpoint & Test, Application, End User and By Geography

According to Stratistics MRC, the Global In-vitro Toxicology Testing Market is accounted for $12.6 billion in 2023 and is expected to reach $29.3 billion by 2030 growing at a CAGR of 12.8% during the forecast period. A scientific method used to assess the potential toxicity of chemicals, pharmaceuticals, consumer goods, and environmental pollutants without using animals is in-vitro toxicology testing, often known as non-animal testing. With this approach, studies are carried out on biological systems, such as separated cells, tissues, or organs, from living creatures. In-vitro testing has a number of benefits, such as cost effectiveness, the potential for quicker findings, and ethical issues is a useful technique in drug development, chemical safety evaluation, and environmental toxicity research because it is typically quicker, more cost-effective, and delivers data that is applicable to humans.

The global pharmaceutical industry spent USD 165 billion on R&D in 2017, according to the IFPMA (2019). The top two industries for R&D spending are the pharmaceutical and biotechnology sectors, with the EU taking the lead in this category, followed by the US, Japan, and China.

Market Dynamics:

Driver:

Increasing government and institutional support in halting animal testing

The usage of in-vitro toxicity testing may expand throughout the projection period as a result of the growing positive government efforts that are extremely concerned with outlawing animal experimentation. In-vitro test technique development is receiving more funding from governmental and commercial organizations. By reducing the reliance on animal models for the safe assessment of novel chemical formulations and compounds, funding initiatives often aim to protect human health, animal health, and the environment. Furthermore, a major factor driving market revenue growth is the rising need for affordable and risk-free substitutes for animal testing in the cosmetics, food, and pharmaceutical industries.

Restraint:

Limited predictive value due to the complexity of human biology

Tests conducted in-vitro might not be very predictive of complicated in-vivo reactions. It is difficult to precisely forecast results in the actual world because human biology comprises many interrelated, interacting elements, and in-vitro simulations may not represent the entire range of these relationships. Chronic circumstances, which arise gradually over time, are difficult to reproduce in in-vitro environments and these disorders frequently require intricate, protracted interactions among many biological elements. Individual cells, tissues, or organs are frequently the subject of in-vitro models. The interconnections between several organ systems, such as the liver, kidney, and immune system, may not be fully replicated by this method which impedes the market.

Opportunity:

Technological advancement

Due to the on-going technological improvements, particularly in the healthcare industry, throughout the anticipated time and these tests are seen to be more widely used as a result of the increasing usage of technology like 3D cell culture models and high-throughput screening. Modern technologies promise to lessen the need on animal testing and assist specialists in gathering more accurate and pertinent information about the toxicity of chemicals. Another industry innovation that will present opportunities over the projection period is the automation of several systems. System automation enables accurate data analysis. By accelerating the pace of drug testing, technological developments enable firms to carry out processes that are both time and cost-effective.

Threat:

Lack of skilled professionals

Tests in in-vitro toxicology demand proficiency in experimental planning, cell culture methods, data processing, and result interpretation. The accuracy and dependability of the results may be jeopardized by testing mistakes and discrepancies brought on by a lack of qualified personnel. It might be challenging to infer significant findings from in-vitro tests due to inconsistent testing methods used by less experienced individuals. Accurate safety evaluations are hampered as a result.

COVID-19 Impact

During the early stages of the pandemic, several labs and research facilities experienced temporary closures or curtailed operations. This slowed down the start of new research and caused delays in programs that were already underway for in-vitro toxicity testing. The pandemic affected the availability of reagents, chemicals, and laboratory supplies required for in-vitro testing. This was due to the disruption of worldwide supply networks. Testing facilities experienced delays and higher expenses as a result. New medications and chemicals were difficult for regulatory organizations like the U.S. FDA and the European Medicines Agency (EMA) to assess and approve. The need for toxicological testing services was thus impacted.

The cell culture technology segment is expected to be the largest during the forecast period

The cell culture technology segment is estimated to have a lucrative growth, because of the expansion and development of in-vitro assay systems, which are predictive, demonstrative, and appropriate for toxicity screening of a varied range of chemicals including nanomaterials and airborne materials, have been made possible by recent inventions and advances in human cell culture exposure as well as test systems. In-vitro toxicology is the study of the hazardous characteristics of diverse substances and combinations utilizing cells or tissues generated or maintained in a controlled laboratory environment. As a result, it is possible to analyze the toxicity of xenobiotics at the fundamental level of the cell without having to consider the interaction of complicated physiological consequences, which are frequently seen in whole animals.

The systemic toxicology segment is expected to have the highest CAGR during the forecast period

The systemic toxicology segment is anticipated to witness the highest CAGR growth during the forecast period, as it entails assessing how these drugs affect different physiological and biochemical processes, frequently employing in-vitro or non-animal testing techniques. Systemic toxicology evaluates a substance's possible systemic effects, including how they are distributed throughout the body, how they are metabolized, and how they affect critical organ systems such the immunological, respiratory, cardiovascular, and brain systems. Moreover to evaluate the safety and effectiveness of medications, chemicals, and other items, the pharmaceutical and chemical industries frequently utilize systemic toxicity testing. In the process of developing new drugs, it is essential.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the fast growth of creative, cost-effective testing for determining the safety of drugs, devices, chemicals, and cosmetics in North America has occurred during the past several years as a result of technological breakthroughs and legislation supported by the government. Currently, clients are able to build toxicological profiles of medical devices, biopharmaceuticals, cosmetics, and chemicals thanks to the major rise in equipment investment and the continued expansion of laboratory capacities throughout the area. Along with the introduction of high throughput screening, automation, and multiplexing technologies for biomarker analysis, these expenditures also involve an extension of the current mass spectrometry, flow cytometry, and cell/tissue culture facilities. Hence all the above factors are driving the growth of the market.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, because this method is thought to be more moral and frequently more affordable than traditional animal testing. In nations like China, India, South Korea, and Japan, the pharmaceutical and biotechnology industries have grown tremendously. The need for these tests is fuelled by the use of in-vitro toxicology testing to evaluate the effectiveness and safety of medication candidates. Stricter standards are being implemented by regulatory agencies in the Asia-Pacific area for the evaluation of the safety of medications and chemicals. In-vitro testing is now more necessary than ever to satisfy regulatory standards which is driving the market.

Key players in the market

Some of the key players profiled in the In-vitro Toxicology Testing Market include: Agilent Technologies, Abbott Laboratories, Covance, Bio-Rad Laboratories, GE Healthcare, Promega Corporation, Quest Diagnostics, Thermo Fisher Scientific, Merck KGaA, Eurofins Scientific, Evotec, Gentronix, BioIVT, Agilent Technologies, Catalent, Inc., Thermo Fisher Scientific Inc., Charles River, Helsinn Holding S.A., Laboratory Corporation of America Holdings and Heron Therapeutics Inc,

Key Developments:

In October 2023, Agilent and Sarawak Infectious Disease Centre Partner to Boost Neglected Tropical Diseases Research in East Malaysia, The agreement scope includes the provision of an Agilent 6475 triple quadrupole LC/MS system to boost the research advancement of neglected tropical diseases (NTDs) and other areas of disease over the next three years.

In October 2023, Labcorp and Baystate Health Announce Strategic Relationship for Diagnostic Laboratory Services. This strategic relationship will build upon Labcorp's and Baystate Health's existing reference laboratory relationship to improve the efficiency of routine and specialty lab testing.

In September 2023, Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers, the scope of the agreement includes the supply of an Agilent Magnis Next-Generation Sequencing (NGS) Preparation System.

In September 2023, Abbott and Bigfoot Biomedical announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes.

Product Types Covered:

• Software
• Assay Kits
• Equipment
• Consumables
• Other Product Types

Methods Covered:

• Cellular Assay
• In Silica
• Biochemical Assay

Technologies Covered:

• Molecular Imaging
• High Throughput Technology
• Cell Culture Technology
• OMICS Technology
• Other Technologies

Toxicity Endpoint & Tests Covered:

• Genotoxicity
• Cytotoxicity
• Organ Toxicity
• Phototoxicity
• Dermal Toxicity
• Kin irritation, Corrosion, & Sensitization
• Absorption, Distribution, Metabolism, & Excretion
• Other Toxicity Endpoint & Tests

Applications Covered:

• Endocrine Disruption
• Systemic Toxicology
• Occular Toxicity
• Other Applications

End Users Covered:

• Pharmaceuticals Industry
• Cosmetics and Households Products
• Food Industry
• Chemicals Industry
• Diagnostics
• Academic Institutes & Research Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances